Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

Dovitinib

"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"

DRUG

Bortezomib

"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"

DRUG

Dexamethasone

Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Florida

OTHER